SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Medpace Holdings, Inc. Common Stock
MEDP
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Last trade$646.87
Day change-$1.33 (-0.21%)
Day range$612.46 – $669.91
Volume85,232
Market cap$18.13B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$18.13B
Price / earnings
35.01×
Price / book
31×
Price / sales
6.39×
EV / sales
6.14×
EV / EBITDA
27.47×
Profitability
Earnings per share
$18.51
Return on assets
22.49%
Return on equity
88.53%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
0.83×
Quick ratio
0.83×
Cash ratio
0.47×
Cash flow
Price / cash flow
25.08×
Price / free cash flow
27.16×
Free cash flow
$667.63M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MEDP, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$716M
$707.33M
$706.6M
$708.45M
$659.9M
$603.31M
$558.57M
$536.59M
Cost of revenue
$492.12M
$505.69M
$510.28M
$503.13M
$462.96M
$423.3M
$380.22M
$358.27M
Gross profit
$223.89M
$201.64M
$196.33M
$205.32M
$196.94M
$180.01M
$178.35M
$178.32M
Selling, general and administrative
$51.77M
$48.1M
$47.92M
$44.92M
$48.08M
$46.66M
$57.9M
$45.43M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$58.35M
$54.81M
$54.82M
$52.05M
$55.13M
$53.68M
$64.83M
$52.94M
Operating income
$165.54M
$146.82M
$141.5M
$153.27M
$141.81M
$126.34M
$113.52M
$125.38M
Interest expense
$5.35M
$0
$0
$0
$1.52M
$0
$0
$0
Income before taxes
$170.91M
$151.66M
$147.59M
$156.83M
$142.84M
$124.54M
$118.17M
$133.88M
Income taxes
$33.45M
$30.3M
$23.72M
$21.7M
$31.7M
$34.28M
$3.58M
$16.86M
Net income
$137.46M
$121.36M
$123.87M
$135.13M
$111.14M
$90.26M
$114.6M
$117.02M
Net income attributable to common shareholders
$137.46M
$121.36M
$123.87M
$135.13M
$111.14M
$90.26M
$114.6M
$117.02M
EBITDA
$172.12M
$153.53M
$148.41M
$160.4M
$148.86M
$133.35M
$120.45M
$132.88M
Basic earnings per share
$4.92
$4.31
$4.35
$4.78
$3.95
$3.16
$3.77
$3.78
Diluted earnings per share
$4.84
$4.25
$4.28
$4.67
$3.86
$3.10
$3.67
$3.67
Recent news
Company coverage with links to the original publishers.
Medpace Holdings (MEDP) is drawing attention from options traders due to high implied volatility in its December 2026 $370 put options, suggesting market expectations for significant price movement. Despite the volatility, the company maintains a Zacks Rank #2 (Buy) rating with analysts raising earnings estimates for the current quarter from $4.64 to $4.82 per share over the last 30 days.
Medpace (MEDP) is highlighted as a compelling growth stock opportunity, combining a Growth Score of B with a Zacks Rank #2 (Buy). The company demonstrates strong fundamentals including 18.2% projected EPS growth (above the 14% industry average), robust cash flow growth of 10.5% year-over-year, and positive earnings estimate revisions with a 3% surge over the past month.
Alcon Inc. (ALC) reported Q3 2026 core EPS of 91 cents, beating estimates by 2.3%, but net sales of $2.72 billion missed consensus by 0.6%. While Vision Care and Equipment segments showed strength, Implantables sales declined 2% due to competitive pressures. The company narrowed its 2026 guidance, expecting 6% constant-currency net sales growth and 12-14% core EPS growth, which weighed on investor sentiment.
Natera (NTRA) reported Q3 2026 results with adjusted EPS loss of 39 cents missing estimates, but revenues of $794 million beat expectations with 34.1% year-over-year growth. Oncology test volumes surged 60.9% and MRD testing showed strong momentum. The company raised its 2026 revenue guidance to $3.005-$3.035 billion and maintained positive cash flow expectations, though operating losses remain a concern.
A $1,000 investment in Medpace (MEDP) made in November 2016 would be worth $20,503.07 as of November 6, 2026, representing a 1,950.31% gain. The clinical contract research organization has demonstrated strong performance with $2.5 billion in fiscal 2025 revenue (up 20% YoY), record third-quarter awards, and a $3.17 billion backlog. However, analysts note revenue growth has moderated, cancellations remain unpredictable, and planned campus costs could restrain 2027 profitability.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.